Ingredient or product comparison
Mechanism Comparison: GHK-Cu vs AHK-Cu in Follicular Activation
GHK-Cu (glycyl-L-histidyl-L-lysine:copper) and AHK-Cu (alanyl-histidyl-lysine:copper) share a tripeptide backbone but diverge completely at the mechanistic level. GHK-Cu binds primarily to integrin α2β1 receptors on dermal papilla cells and follicular keratino
This source-based comparison does not add ratings or recommend a winner.
- GHK-Cu (glycyl-L-histidyl-L-lysine:copper) and AHK-Cu (alanyl-histidyl-lysine:copper) share a tripeptide backbone but diverge completely at the mechanistic level. GHK-Cu binds primarily to integrin α2β1 receptors on dermal papilla cells and follicular keratinocytes—triggering downstream VEGF-A expression, which increases capillary formation around miniaturized follicles. In vitro studies demonstrate that GHK-Cu at 1–5 µM concentrations increases microvascular density by 18–24% within 14 days in dermal papilla cell cultures. This angiogenic effect matters because hair follicles in androgenetic alopecia show significant microvascular regression—follicular blood flow decreases by 40–60% before visible miniaturization occurs. GHK-Cu doesn't reverse miniaturization directly; it restores the vascular scaffold required for follicles to sustain anagen phase beyond 2–3 months.
- AHK-Cu operates through a separate pathway entirely: selective inhibition of TGF-β1 signalling in follicular dermal papilla cells. Elevated TGF-β1 is the primary inflammatory cytokine that drives premature catagen entry—it suppresses Wnt/β-catenin signalling (the pathway that keeps follicles in anagen) and upregulates DKK-1, a Wnt antagonist. AHK-Cu binds to TGF-β type I receptors and blocks downstream Smad2/3 phosphorylation—the intracellular signal that triggers follicular regression. Clinical data from a 2023 Korean dermatology trial found that AHK-Cu at 0.5–2 mM concentrations extended anagen duration by an average of 42 days in participants with pattern hair loss. The GHK-Cu AHK-Cu stack hair growth dual copper protocol 2026 leverages both mechanisms: GHK-Cu rebuilds follicular vasculature while AHK-Cu prevents the inflammatory trigger that would otherwise arrest growth despite improved blood flow. Stacking them addresses two independent bottlenecks in the miniaturization cycle—no